UPDATED: Hedge fund aims to oust Depomed board for ‘troubling record’

Eric Palmer If Depomed thought it was free to chart its own course after foiling a takeover by Horizon Pharma last year, it can think again. A hedge fund practiced in the art of board ...

Pressure mounts at GSK, with U.S. hedge fund leading calls for exec shakeup

Tracy Staton Another big investor is putting the screws to GlaxoSmith Kline. Och-Ziff Capital Management has built up a sizable stake in the London-based drugmaker, The Sunday Times ...

Galapagos advances AbbVie-partnered CF drug; UCL forms £50M fund; Vasopharm bags €20M

Nick Paul Taylor In this week's EuroBiotech Report, the first of two correctors destined for use in Galapagos' triple-hit cystic fibrosis therapy is now in the clinic. With ...

China’s Cocoon rolls out a $720M fund to back U.K. biotechs; AbbVie teams up with MD Anderson on immuno-oncology;

Alok Saboo FierceBiotech News

Vasopharm taps investors for €20M to fund PhIII trial of brain injury treatment

Nick Paul Taylor Vasopharm has emerged from talks with investors armed with €20 million ($ 22 million) to hustle its treatment for traumatic brain injury through Phase III. The ...

Abingworth tees up a unique, $105M co-development fund for PhIII deals

John Carroll The international team at Abingworth likes investing in co-development programs, backing two companies that specialize in taking on the risk and cost of Phase III in exchange ...

UCL sets up £50M VC fund to support academic spinouts

Nick Paul Taylor University College London (UCL) is getting into the venture capital game. The university, which has spawned a host of biotechs, has rounded up £50 million ($ ...

China’s BeiGene pitches a $150M IPO to fund its cancer pipeline

Damian Garde Chinese biotech BeiGene is hoping to trade on the Nasdaq, filing for an IPO worth more than $ 150 million to support its pipeline of targeted cancer drugs. FierceBiotech ...

Crossovers fund a $61M round for Twist Bio, spotlighting possible IPO

John Carroll Just 7 months after coming up with a $ 37 million Series C, Twist Bioscience has gone back to the well and drawn up another $ 61 million in private investor cash. That ...

Ysios, J&J back €11.5M round in Aelix to fund trials of HIV treatment

Nick Paul Taylor Aelix Therapeutics has raised €11.5 million ($ 12.6 million) to advance a therapeutic HIV candidate to clinical proof of concept. Ysios Capital, Johnson & ...

OrbiMed rings up $950M for its transatlantic biotech Fund VI

John Carroll OrbiMed has come through with a whopping $ 950 million biotech venture fund, committing anywhere from $ 10 million to a hefty $ 75 million to each of about 30 new companies. FierceBiotech ...

Novartis backs $176M microbiome biotech fund

John Carroll Novartis has stepped in to back Paris-based Seventure Partners' biotech fund focused exclusively on the emerging field of the microbiome as well as nutrition, bringing ...
Page 1 of 512345
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS